Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
13.84
-0.54 (-3.76%)
At close: Sep 4, 2026, 4:00 PM EDT
13.84
0.00 (0.00%)
After-hours: Sep 4, 2026, 4:10 PM EDT
Monte Rosa Therapeutics Employees
Monte Rosa Therapeutics had 173 employees as of June 30, 2026. The number of employees increased by 31 or 21.83% compared to the same quarter last year.
Employees
173
Change
31
Growth
21.83%
Revenue / Employee
$166,052
Profits / Employee
-$931,306
Market Cap
1.18B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 173 | 31 | 21.83% |
| Mar 31, 2026 | 161 | 19 | 13.38% |
| Dec 31, 2025 | 150 | 16 | 11.94% |
| Sep 30, 2025 | 147 | 14 | 10.53% |
| Jun 30, 2025 | 142 | 13 | 10.08% |
| Mar 31, 2025 | 142 | 12 | 9.23% |
| Dec 31, 2024 | 134 | 1 | 0.75% |
| Sep 30, 2024 | 133 | 0 | - |
| Jun 30, 2024 | 129 | -4 | -3.01% |
| Mar 31, 2024 | 130 | -3 | -2.26% |
| Dec 31, 2023 | 133 | 10 | 8.13% |
| Sep 30, 2023 | 133 | 15 | 12.71% |
| Jun 30, 2023 | 133 | 29 | 27.88% |
| Mar 31, 2023 | 133 | 38 | 40.00% |
| Dec 31, 2022 | 123 | 30 | 32.26% |
| Sep 30, 2022 | 118 | 24 | 25.53% |
| Jun 30, 2022 | 104 | 21 | 25.30% |
| Mar 31, 2022 | 95 | 35 | 58.33% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 704 |
| MannKind | 592 |
| Kura Oncology | 260 |
| Sana Biotechnology | 142 |
| MoonLake Immunotherapeutics | 130 |
| Janux Therapeutics | 113 |
| ORIC Pharmaceuticals | 111 |
| Odyssey Therapeutics | 100 |
GLUE News
- 2 days ago - Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 days ago - Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 11 days ago - Monte Rosa Therapeutics doses first patient in MODeFIRe-1 trial - TheFly
- 11 days ago - Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 4 weeks ago - Monte Rosa Therapeutics price target lowered to $28 from $35 at Guggenheim - TheFly
- 4 weeks ago - Monte Rosa Therapeutics reports Q2 revenue $8.97M, consensus $12.88M - TheFly
- 4 weeks ago - Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - GlobeNewsWire
- 4 weeks ago - Monte Rosa Therapeutics Quarterly report: Q2 2026 - Filings